Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.53 |
| ▸ | MAOB | P27338 | 3/20 | 0.46 |
| ▸ | ACHE | P22303 | 2/20 | 0.46 |
| ▸ | MAOA | P21397 | 2/20 | 0.46 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.46 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.45 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8935814 | 0.88 | MAOA (0.59) | MAP2K1MAOBACHEMAOA | |
| SCHEMBL8934780 | 0.86 | ROCK1 (0.56) | MAOBMAOAROCK1 | |
| SCHEMBL8935808 | 0.85 | MAOB (0.59) | MAP2K1MAOBACHEMAOA | |
| SCHEMBL8935887 | 0.84 | MAP2K1 (0.55) | MAP2K1MAOBACHEMAOAROCK1 | |
| SCHEMBL8935934 | 0.83 | MAP2K1 (0.53) | MAP2K1MAOBACHEMAOAROCK1 | |
| SCHEMBL8935917 | 0.82 | MAP2K1 (0.55) | MAP2K1MAOBACHEMAOA | |
| SCHEMBL8938922 | 0.82 | MAP2K1 (0.55) | MAP2K1MAOBACHEMAOA | |
| SCHEMBL8935619 | 0.81 | MAP2K1 (0.61) | MAP2K1ROCK1 | |
| SCHEMBL8935674 | 0.81 | MAP2K1 (0.61) | MAP2K1ROCK1 | |
| SCHEMBL8938927 | 0.81 | MAOB (0.52) | MAP2K1MAOBACHEMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2385047-B1 | Piperidinyl-substituted isoquinolone derivatives | SANOFI SA (FR) | 2013-05-29 | — | — | EP | disclosed |
| US-8188117-B2 | Piperidinyl-substituted isoquinolone derivatives | SANOFI-AVENTIS (FR) | 2012-05-29 | — | — | US | disclosed |
| US-8188117-B2 | Piperidinyl-substituted isoquinolone derivatives | SANOFI-AVENTIS (FR) | 2012-05-29 | — | — | US | disclosed |
| EP-2385047-A1 | Piperidinyl-substituted isoquinolone derivatives | SANOFI (FR) | 2011-11-09 | — | — | EP | disclosed |
| US-20090093518-A1 | Piperidinyl-substituted isoquinolone derivatives | SANOFI-AVENTIS (FR) | 2009-04-09 | — | — | US | disclosed |
| US-20090093518-A1 | Piperidinyl-substituted isoquinolone derivatives | SANOFI-AVENTIS (FR) | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093518-A1 | Piperidinyl-substituted isoquinolone derivatives | MYLK2, MYLK, RHOT2 | MAP2K1 1916/4885MAOB 2595/4885ACHE 3559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.